**Description of CiNA Public Use Dataset**

**The NAACCR CiNA-Public Dataset** is a new CiNA product that was first available for 1995-2013 data and is updated with most recent diagnosis year annually in early summer. The goal behind producing the CiNA Public Use Dataset is to provide faster, streamlined access to the CiNA data in order to increase CiNA data use and, ultimately, reduce the burden of cancer. The data will be available annually after publication of the CiNA monographs; generally in the summer.

The CiNA Public Use Dataset is a publically accessible, non-confidential data set with a limited number of variables, available in the SEER\*Stat program. Access requires only a signed Data Assurances Agreement for access. There are other CiNA databases with more extensive variable set that require a proposal review, NAACCR IRB approval, and a “yes” consent by each participating registry. The CiNA Public Use variable list is included at the end of this document. Many variables are recoded from the reported data for ease of use and standardization of analysis. There are no treatment variables available in the CiNA Public Use Dataset.

The dataset is released through the SEER\*Stat system and a user may generate counts, rates and tends. This dataset includes age in the 19 age group categories. No case-level data is exportable from CiNA Public Use. SEER\*Stat provides automatic cell suppression of <6 and scrambles the Patient IDs. *At this time, the database allowing exporting is still under development.*

Additional details about the CiNA Public Use Dataset are provided in this document. If you have questions about the NAACCR CiNA Public Dataset, please contact Recinda Sherman, Manager of Research and Data Use at [rsherman@naaccr.org](mailto:rsherman@naaccr.org) or 217-698-0800 x6. A list of variables in the Public Use Dataset can be found here: <https://www.naaccr.org/cina-public-use-data-set/>

**Data Use Agreement for Researcher Access to the Public Use Data Set**

**NAACCR CiNA-Public Dataset**

These data are provided for the sole purpose of statistical reporting and analysis only. By using these data, you signify your agreement to comply with the following:

1. There will be no attempt to learn the identity of any person included in these data. If the identity of any person is discovered inadvertently, no disclosure or other use of the identity will be made, ***and I will notify NAACCR***.

**Initials required: \_\_\_\_**

1. The identification or contact of individuals is prohibited. I will not discuss in any manner, with any unauthorized person, information that would lead to identification of individuals described in the Data furnished by NAACCR.

**Initials required: \_\_\_\_**

1. I will not attempt either to link—***or permit others to link***—the data with individually identified records in another database.

**Initials required: \_\_\_\_**

1. I will not either release—***or permit others to release***—the data—in full or in part—to any person. I will not share my password for data access with any other individuals. All members of a research team who have access to the data must sign this data-use agreement.

**Initials required: \_\_\_\_**

1. I will not use—or permit others to use—the data in any way other than for statistical reporting and analysis for public health research purposes. I must notify NAACCR if I discover that there has been any other use of the data.

**Initials required: \_\_\_\_**

1. I agree that all data provided shall remain the sole property of NAACCR and may not be copied or reproduced in any form or manner without NAACCR's prior written consent.

**Initials required: \_\_\_\_**

1. I will cite the source of information in all publications. The appropriate citation is associated with the data file used.

**Initials required: \_\_\_\_**

1. Uses of these data do not constitute an endorsement of the user's opinion or conclusions by NAACCR, or any central registry in US or Canada, and none should be inferred.

**Initials required: \_\_\_\_**

1. I understand that calculating rates or other statistics based on small numbers can raise statistical issues concerning accuracy and usefulness. I will use appropriate caution when presenting and interpreting results based on less than 20 cases.

**Initials required: \_\_\_\_**

1. I agree that any and all reports or analyses of the Data shall contain only aggregate data and no report of the Data containing statistical cells with less than six (6) subjects shall be released.

**Initials required: \_\_\_\_**

My signature indicates that I agree to comply with the above stated provisions.

First Name: Last Name:

Organization: Email:

Phone:

Date: Signature:

Questions or issues, please contact Recinda Sherman, [rsherman@naaccr.org](mailto:rsherman@naaccr.org).

**Citation**

Please reference to the source of these data in any published document as indicated in SEER\*Stat session.

For example:

NAACCR Incidence - CiNA Public File, 1995-2015 (which includes data from CDC’s National Program of Cancer Registries (NPCR), CCCR’s Provincial and Territorial Registries, and the NCI’s Surveillance, Epidemiology and End Results (SEER) Registries), North American Association of Central Cancer Registries.

**Technical Documentation**

The NAACCR CiNA-Public Dataset is distributed through SEER\*Stat and contains individual records of cancer incidence among US and Canada residents diagnosed from 1995 – 2015. Confidentiality is maintained by aggregating data within individual records into categories, the number of which depends on whether analysis is run on individual states/registries or nation/North America.

The purpose of releasing cancer surveillance data is to inform public health decision making. Cancer rates are often needed for subgroups or for small populations in order to understand the burden of cancer in these groups or areas. But working with small numbers has two problems 1) working with small numbers, particularly linking with external data, has the potential for confidentiality breaches; and 2) small numbers raise statistical issues regarding the accuracy and, ultimately, the usefulness of the data.

* To preserve confidentiality of the data, data will be automatically suppressed for counts less than 6 based on potentially linkable variables (registry, sex, age, race, race/ethnicity, year of diagnosis and site). Please note, counts less than six may be released for other variables including behavior, stage or histology. However, these variables are not considered identifying variables.
* For issues of statistically stability, we advise caution in interpreting rates and other results based on fewer than 25 cases.

**Software**

SEER\*Stat statistical software is a standard tool for analysis of cancer-related data. SEER\*Stat is distributed with the CiNA Public Dataset. Additional information on SEER\*Stat is available on the NCI, SEER site: <http://seer.cancer.gov/seerstat/>. Tutorials are available here: <http://seer.cancer.gov/seerstat/tutorials/>. Delay factors, survival statistics, and prevalence are not currently available for the CiNA Public Dataset.

**Representation**

To be included in the CiNA Public dataset, a central registry from the US or Canada must meet specific data quality standards. All Gold and Silver NAACCR-certified central registries are eligible for inclusion in the CiNA Public dataset. Each central registry must also consent to the use of their data in the CiNA Public dataset. A current list of certified registries is available here: <https://www.naaccr.org/certified-registries/>. Registries may have not been certified in prior years, but if their data quality improves over time, their data is included in CiNA. However, not all states meet the data quality criteria for each year and will have zero counts for those years. Current CiNA Public Use dataset contains 46 states plus DC and PR for the US, and 12 Canadian provinces covering 93% of the US and 64% of the Canada population.

**Data Collection**

Cancer registry data is collected in an on-going, systematic, and standardized process. In Canada, the cancer registry collection program is overseen by the Canadian Council of Cancer Registries. In the US, there are two cancer registry collection programs—the National Cancer Institute’s Surveillance, Epidemiology and End Results (SEER Program) and the Center for Disease Control’s National Program of Cancer Registries (NPCR). Data for all three programs is collected in a coordinated process from hospitals and other medical facilities, including inpatient, outpatient, and standalone facilities. The data is collected or overseen by certified tumor registrars (CTRs) who are highly trained medical professionals to ensure complete and high quality data collection. The International Classification of Disease-Oncology (ICD-O) coding system is used to code topography (primary site) and morphology (histologic characteristics) of the collected cancers. Additional coding information is available in the NAACCR Data Standards & Data Dictionary (Volume II) available here: <https://www.naaccr.org/data-standards-data-dictionary/>.

Please note, the variables available in the CiNA Public Dataset are a subset of the full variable list collected. Many variables in the CiNA Public Dataset are aggregated and recoded for analysis.

**Cancer Coding Changes Over Time**

Several definitional changes occurred in some histology and behavior codes in ICD-O-3 that affected the inclusion and exclusion of reportable cancers diagnosed beginning in 2001.The changes predominately affected leukemias, lymphomas, and cancer of the ovary. One category of change between ICD-O-2 and ICD-O-3 is the manner in which leukemias and lymphomas are classified and coded. Although conversion of histology codes from ICD-O-2 to ICD-O-3 for cases diagnosed prior to 2001 helps minimize these differences, some minor differences may still exist, particularly with respect to some relatively rare lymphocytic cancers that can be coded to either leukemia or lymphoma.

Starting with ICD-O-3, several myelodysplastic diseases and syndromes are considered malignant, and, therefore, are now reportable for cases diagnosed in 2001 and later and are included in these data. Leukemias that represent a disease progression from one of the myelodysplastic diseases or syndromes diagnosed in 2001 and forward are no longer reportable.

For pediatric cancers, differences in incidence rates may be due to changes between the second and third edition of the International Classification of Childhood Cancers (ICCC). Two changes in the ICCC-3 classification are main contributors to this change. 1) Burkitt lymphoma and unspecified lymphoma, which were separated from non-Hodgkin lymphoma previously are combined with non-Hodgkin lymphoma; 2) Some lymphomas, which were grouped in the miscellaneous lymphoreticular neoplasms previously, are now included in the non-Hodgkin lymphoma category. Pilocytic astrocytoma is considered to have uncertain behavior in the published version of ICD-O-3, but is reportable as a malignant cancer in North America. Including the childhood astrocytomas in the category of malignant brain tumors may introduce differences between childhood brain cancer rates in North America compared to other areas of the world that may not include these tumors as malignant.

In addition, mesothelioma and Kaposi sarcoma cases are reported as separate categories. This change has little or no impact on most rates for specific cancers.

**Variable List**

|  |  |
| --- | --- |
| Demographic | State/Province |
| Demographic | Recode: Country |
| Demographic | Recode: Sex |
| Demographic | Recode: Age |
| Demographic | Recode: Race |
| Demographic | Recode: Hispanic |
| Cancer ID | Recode: Central Seq # |
| Cancer ID | Dx date year only |
| Cancer ID | Recode: Behavior |
| Cancer ID | Recode: Primary Site plus with Meso & KS |
| Cancer ID | Recode: ICCC |
| *Cancer ID* | *Recode: CBTRUS for brain—under development* |
| Cancer ID | Recode: Histology |
| Cancer ID | Recode: Summary Stage |
| Cancer ID | Laterality |
| Cancer ID | Grade |
| Cancer ID | Recode: Diagnostic confirmation |
| Cancer ID | Recode: Report Source |
| Derived | MP using IARC rules & SEER |
| Derived | County-Level Urban/Rural Status Code |
| Derived | County-Level Poverty Code |
| *Derived* | *SES Composite (SEER)—under development* |

**Variable Codes:**

*State:* Name of state/province (Will include only high quality registries following CiNA monograph standards)

*Country*: 2 codes (US, Canada)—Derived code

*Sex:* T (includes all categories), M, F, unk

*Age:* 5-year aggregates; 0-4, 5-9,…75-79, 80-84, 85+,  **no unknown age**

*Race*: (US only)

National: W, B, API, AIAN (AIAN is based on CHDSA counties only; recoded into race variable), Unk; and W, B, O, unk. Race suppressed following CiNA monograph standards (<6 in numerator).

*Race/ethnicity:*

Hispanic All Races, Non-Hispanic White, Non-Hispanic Black, Non-Hispanic Other, Non-Hispanic Unknown Race, Unknown Hispanic (based on NHIA). Race/ethnicity suppressed following CiNA monograph standards (<6 in numerator).

*Central Seq #:* variable collapsed

One primary only, 1st of 2 or more primaries; 2nd of 2 or more primaries; 3rd of 3 or more primaries, 4th of 4 or more primaries; 5th of 5 or more primaries; 6th or more of 6 or more primaries

*Year of Diagnosis:* 1995-most current available

*Behavior:*

Benign, Borderline, In situ, Malignant, Only Malignant in ICD-O-3, No longer Reportable in ICD-O-3, Only malignant 2010+


*Primary Site (03):* based on ICD-O-3 regardless of diagnosis date; suppression rules apply


|  |
| --- |
| All Sites |
| Oral Cavity and Pharynx |
| Lip |
| Tongue |
| Salivary Gland |
| Floor of Mouth |
| Gum and Other Mouth |
| Nasopharynx |
| Tonsil |
| Oropharynx |
| Hypopharynx |
| Other Oral Cavity and Pharynx |
| Digestive System |
| Esophagus |
| Stomach |
| Small Intestine |
| Colon and Rectum |
| Colon excluding Rectum |
| Cecum |
| Appendix |
| Ascending Colon |
| Hepatic Flexure |
| Transverse Colon |
| Splenic Flexure |
| Descending Colon |
| Sigmoid Colon |
| Large Intestine, NOS |
| Rectum and Rectosigmoid Junction |
| Rectosigmoid Junction |
| Rectum |
| Anus, Anal Canal and Anorectum |
| Liver and Intrahepatic Bile Duct |
| Liver |
| Intrahepatic Bile Duct |
| Gallbladder |
| Other Biliary |
| Pancreas |
| Retroperitoneum |
| Peritoneum, Omentum and Mesentery |
| Other Digestive Organs |
| Respiratory System |
| Nose, Nasal Cavity and Middle Ear |
| Larynx |
| Lung and Bronchus |
| Pleura |
| Trachea, Mediastinum and Other Respiratory Organs |
| Bones and Joints |
| Soft Tissue including Heart |
| Skin excluding Basal and Squamous |
| Melanoma of the Skin |
| Other Non-Epithelial Skin |
| Breast |
| Female Genital System |
| Cervix Uteri |
| Corpus and Uterus, NOS |
| Corpus Uteri |
| Uterus, NOS |
| Ovary |
| Vagina |
| Vulva |
| Other Female Genital Organs |
| Male Genital System |
| Prostate |
| Testis |
| Penis |
| Other Male Genital Organs |
| Urinary System |
| Urinary Bladder |
| Kidney and Renal Pelvis |
| Ureter |
| Other Urinary Organs |
| Eye and Orbit |
| Brain and Other Nervous System |
| Brain |
| Cranial Nerves Other Nervous System |
| Endocrine System |
| Thyroid |
| Other Endocrine including Thymus |
| Lymphoma |
| Hodgkin Lymphoma |
| Hodgkin - Nodal |
| Hodgkin - Extranodal |
| Non-Hodgkin Lymphoma |
| NHL - Nodal |
| NHL - Extranodal |
| Myeloma |
| Leukemia |
| Lymphocytic Leukemia |
| Acute Lymphocytic Leukemia |
| Chronic Lymphocytic Leukemia |
| Other Lymphocytic Leukemia |
| Myeloid and Monocytic Leukemia |
| Acute Myeloid Leukemia |
| Acute Monocytic Leukemia |
| Chronic Myeloid Leukemia |
| Other Myeloid/Monocytic Leukemia |
| Other Leukemia |
| Other Acute Leukemia |
| Aleukemic, Subleukemic and NOS |
| Mesothelioma |
| Kaposi Sarcoma |
| Miscellaneous |


*ICCC:* based on ICD-O-3 regardless of diagnosis date

|  |
| --- |
| I Leukemias, myeloproliferative & myelodysplastic diseases |
| I(a) Lymphoid leukemias |
| I(b) Acute myeloid leukemias |
| I(c) Chronic myeloproliferative diseases |
| I(d) Myelodysplastic syndrome and other myeloproliferative |
| I(e) Unspecified and other specified leukemias |
| II Lymphomas and reticuloendothelial neoplasms |
| II(a) Hodgkin lymphomas |
| II(b) Non-Hodgkin lymphomas (except Burkitt lymphoma) |
| II(c) Burkitt lymphoma |
| II(d) Miscellaneous lymphoreticular neoplasms |
| II(e) Unspecified lymphomas |
| III CNS and misc intracranial and intraspinal neoplasms |
| III(a) Ependymomas and choroid plexus tumor |
| III(b) Astrocytomas |
| III(c) Intracranial and intraspinal embryonal tumors |
| III(d) Other gliomas |
| III(e) Other specified intracranial/intraspinal neoplasms |
| III(f) Unspecified intracranial and intraspinal neoplasms |
| IV Neuroblastoma and other peripheral nervous cell tumors |
| IV(a) Neuroblastoma and ganglioneuroblastoma |
| IV(b) Other peripheral nervous cell tumors |
| V Retinoblastoma |
| VI Renal tumors |
| VI(a) Nephroblastoma and other nonepithelial renal tumors |
| VI(b) Renal carcinomas |
| VI(c) Unspecified malignant renal tumors |
| VII Hepatic tumors |
| VII(a) Hepatoblastoma |
| VII(b) Hepatic carcinomas |
| VII(c) Unspecified malignant hepatic tumors |
| VIII Malignant bone tumors |
| VIII(a) Osteosarcomas |
| VIII(b) Chondrosarcomas |
| VIII(c) Ewing tumor and related sarcomas of bone |
| VIII(d) Other specified malignant bone tumors |
| VIII(e) Unspecified malignant bone tumors |
| IX Soft tissue and other extraosseous sarcomas |
| IX(a) Rhabdomyosarcomas |
| IX(b) Fibrosarcomas, peripheral nerve & other fibrous |
| IX(c) Kaposi sarcoma |
| IX(d) Other specified soft tissue sarcomas |
| IX(e) Unspecified soft tissue sarcomas |
| X Germ cell & trophoblastic tumors & neoplasms of gonads |
| X(a) Intracranial & intraspinal germ cell tumors |
| X(b) Extracranial & extragonadal germ cell tumors |
| X(c) Malignant gonadal germ cell tumors |
| X(d) Gonadal carcinomas |
| X(e) Other and unspecified malignant gonadal tumors |
| XI Other malignant epithelial neoplasms and melanomas |
| XI(a) Adrenocortical carcinomas |
| XI(b) Thyroid carcinomas |
| XI(c) Nasopharyngeal carcinomas |
| XI(d) Malignant melanomas |
| XI(e) Skin carcinomas |
| XI(f) Other and unspecified carcinomas |
| XII Other and unspecified malignant neoplasms |
| XII(a) Other specified malignant tumors |
| XII(b) Other unspecified malignant tumors |
| Not classified by ICCC or in situ |

Appendix A. CBTRUS site/histology groups for malignant and non-malignant brain and CNS tumors. The variable is histologic group for malignant (Table 2b) and non-malignant (Table 2c) brain and CNS tumors (based on Table 1).







*Histology (03):* based on ICD-O-3 regardless of diagnosis date

|  |
| --- |
| 8000/0: Neoplasm, benign |
| 8000/1: Neoplasm, uncertain whether benign or malignant |
| 8000/2: Neoplasm, in situ |
| 8000/3: Neoplasm, malignant |
| 8001/0: Tumor cells, benign |
| 8001/1: Tumor cells, uncertain whether benign or malignant |
| 8001/3: Tumor cells, malignant |
| 8002/3: Malignant tumor, small cell type |
| 8003/1 |
| 8003/3: Malignant tumor, giant cell type |
| 8004/0 |
| 8004/3: Malignant tumor, spindle cell type |
| 8005/1 |
| 8005/3: Malignant tumor, clear cell type |
| 8010/0: Epithelial tumor, benign |
| 8010/1 |
| 8010/2: Carcinoma in situ, NOS |
| 8010/3: Carcinoma, NOS |
| 8011/2: Epithelioma, in situ |
| 8011/3: Epithelioma, malignant |
| 8012/2: Large cell carcinoma in situ |
| 8012/3: Large cell carcinoma, NOS |
| 8013/3: Large cell neuroendocrine carcinoma |
| 8014/2 |
| 8014/3: Large cell carcinoma with rhabdoid phenotype |
| 8015/3: Glassy cell carcinoma |
| 8020/2 |
| 8020/3: Carcinoma, undifferentiated type, NOS |
| 8021/3: Carcinoma, anaplastic type, NOS |
| 8022/2: Pleomorphic carcinoma in situ |
| 8022/3: Pleomorphic carcinoma |
| 8030/2: Giant cell and spindle cell carcinoma in situ |
| 8030/3: Giant cell and spindle cell carcinoma |
| 8031/2: Giant cell carcinoma in situ |
| 8031/3: Giant cell carcinoma |
| 8032/2: Spindle cell carcinoma in situ |
| 8032/3: Spindle cell carcinoma |
| 8033/2: Pseudosarcomatous carcinoma, in situ |
| 8033/3: Pseudosarcomatous carcinoma |
| 8034/3: Polygonal cell carcinoma |
| 8035/3: Carcinoma with osteoclast-like giant cells |
| 8040/1: Tumorlet, NOS |
| 8040/3: Tumorlet, malignant |
| 8041/2: Small cell carcinoma in situ |
| 8041/3: Small cell carcinoma, NOS |
| 8042/2: Oat cell carcinoma in situ |
| 8042/3: Oat cell carcinoma |
| 8043/3: Small cell carcinoma, fusiform cell |
| 8044/3: Small cell carcinoma, intermediate cell |
| 8045/3: Combined small cell carcinoma |
| 8046/2: Non-small cell carcinoma in situ |
| 8046/3: Non-small cell carcinoma |
| 8050/0 |
| 8050/2: Papillary carcinoma in situ |
| 8050/3: Papillary carcinoma, NOS |
| 8051/2: Verrucous papilloma in situ |
| 8051/3: Verrucous carcinoma, NOS |
| 8052/2: Papillary squamous cell carcinoma, non-invasive |
| 8052/3: Papillary squamous cell carcinoma |
| 8053/2 |
| 8053/3: Papillary squamous cell carcinoma, inverted |
| 8060/3 |
| 8070/2: Squamous cell carcinoma in situ, NOS |
| 8070/3: Squamous cell carcinoma, NOS |
| 8071/2: Squamous cell carcinoma in situ, keratinizing, NOS |
| 8071/3: Squamous cell carcinoma, keratinizing, NOS |
| 8072/2: Squamous cell CIS, large cell, nonkeratinizing |
| 8072/3: Squamous cell ca., large cell, nonkeratinizing |
| 8073/2: Squamous cell CIS, small cell, nonkeratinizing |
| 8073/3: Squamous cell ca., small cell, nonkeratinizing |
| 8074/2: Squamous cell carcinoma in situ, spindle cell |
| 8074/3: Squamous cell carcinoma, spindle cell |
| 8075/2: Squamous cell carcinoma in situ, adenoid |
| 8075/3: Squamous cell carcinoma, adenoid |
| 8076/2: Squamous cell CIS with questionable stromal invasion |
| 8076/3: Squamous cell carcinoma, micro-invasive |
| 8077/2: Squamous intraepithelial neoplasia, grade III |
| 8077/3: Squamous cell ca. & Grade III |
| 8078/3: Squamous cell carcinoma with horn formation |
| 8080/2: Queyrat erythroplasia |
| 8080/3: Queyrat erythroplasia, malignant |
| 8081/2: Bowen disease |
| 8081/3: Bowen disease, malignant |
| 8082/3: Lymphoepithelial carcinoma |
| 8083/2: Basaloid squamous cell carcinoma in situ |
| 8083/3: Basaloid squamous cell carcinoma |
| 8084/3: Squamous cell carcinoma, clear cell type |
| 8090/2: Basal cell carcinoma in situ |
| 8090/3: Basal cell carcinoma, NOS |
| 8091/2: Multicentric basal cell carcinoma in situ |
| 8091/3: Multifocal superficial basal cell carcinoma |
| 8092/3: Infiltrating basal cell carcinoma, NOS |
| 8093/3: Basal cell carcinoma, fibroepithelial |
| 8094/2: Basosquamous carcinoma in situ |
| 8094/3: Basosquamous carcinoma |
| 8095/3: Metatypical carcinoma |
| 8097/2 |
| 8097/3: Basal cell carcinoma, nodular |
| 8098/3: Adenoid basal cell carcinoma |
| 8100/3: Trichoepithelioma, malignant |
| 8101/3 |
| 8102/3: Trichilemmocarcinoma |
| 8103/0 |
| 8103/3: Pilar tumor, malignant |
| 8110/3: Pilomatrix carcinoma |
| 8120/0 |
| 8120/2: Transitional cell carcinoma in situ |
| 8120/3: Transitional cell carcinoma, NOS |
| 8121/2: Transitional cell carcinoma in situ, inverted, NOS |
| 8121/3: Schneiderian carcinoma |
| 8122/2 |
| 8122/3: Transitional cell carcinoma, spindle cell |
| 8123/2: Basaloid carcinoma in situ |
| 8123/3: Basaloid carcinoma |
| 8124/2: Cloacogenic carcinoma in situ |
| 8124/3: Cloacogenic carcinoma |
| 8130/2: Papillary transitional cell carcinoma, non-invasive |
| 8130/3: Papillary transitional cell carcinoma |
| 8131/2: Transitional cell carcinoma in situ, micropapillary |
| 8131/3: Transitional cell carcinoma, micropapillary |
| 8140/0: Adenoma, NOS |
| 8140/1: Atypical adenoma |
| 8140/2: Adenocarcinoma in situ |
| 8140/3: Adenocarcinoma, NOS |
| 8141/3: Scirrhous adenocarcinoma |
| 8142/2 |
| 8142/3: Linitis plastica |
| 8143/2: Superficial spreading adenocarcinoma in situ |
| 8143/3: Superficial spreading adenocarcinoma |
| 8144/2: Adenocarcinoma in situ, intestinal type |
| 8144/3: Adenocarcinoma, intestinal type |
| 8145/2: Carcinoma in situ, diffuse type |
| 8145/3: Carcinoma, diffuse type |
| 8146/0: Monomorphic adenoma |
| 8146/3: Monomorphic adenocarcinoma |
| 8147/2 |
| 8147/3: Basal cell adenocarcinoma |
| 8148/2: Glandular intraepithelial neoplasia, grade III |
| 8148/3: Glandular neoplasia, malignant, Grade III |
| 8149/3 |
| 8150/3: Islet cell carcinoma |
| 8151/3: Insulinoma, malignant |
| 8152/3: Glucagonoma, malignant |
| 8153/3: Gastrinoma, malignant |
| 8154/3: Mixed islet cell and exocrine adenocarcinoma |
| 8155/3: Vipoma |
| 8156/3: Somatostatinoma, malignant |
| 8160/2: Bile duct adenocarcinoma in situ |
| 8160/3: Cholangiocarcinoma |
| 8161/3: Bile duct cystadenocarcinoma |
| 8162/2 |
| 8162/3: Klatskin tumor |
| 8170/2: Hepatocellular carcinoma in situ |
| 8170/3: Hepatocellular carcinoma, NOS |
| 8171/3: Hepatocellular carcinoma, fibrolamellar |
| 8172/0 |
| 8172/3: Hepatocellular carcinoma, scirrhous |
| 8173/3: Hepatocellular carcinoma, spindle cell variant |
| 8174/3: Hepatocellular carcinoma, clear cell type |
| 8175/3: Hepatocellular carcinoma, pleomorphic type |
| 8180/2 |
| 8180/3: Combined hepatocellular ca. & cholangiocarcinoma |
| 8190/3: Trabecular adenocarcinoma |
| 8200/2: Adenoid cystic carcinoma in situ |
| 8200/3: Adenoid cystic carcinoma |
| 8201/2: Cribriform carcinoma in situ |
| 8201/3: Cribriform carcinoma |
| 8202/0: Microcystic adenoma |
| 8202/3 |
| 8210/2: Adenocarcinoma in situ in adenomatous polyp |
| 8210/3: Adenocarcinoma in adenomatous polyp |
| 8211/2: Tubular adenocarcinoma in situ |
| 8211/3: Tubular adenocarcinoma |
| 8212/2 |
| 8212/3 |
| 8213/2: Serrated adenocarcinoma, in situ |
| 8213/3: Serrated adenocarcinoma |
| 8214/3: Parietal cell carcinoma |
| 8215/3: Adenocarcinoma of anal glands |
| 8220/2: Adenocarcinoma in situ in adenomatous polyposis coli |
| 8220/3: Adenocarcinoma in adenomatous polyposis coli |
| 8221/2: Adenoca. in situ in mult. adenomatous polyposis coli |
| 8221/3: Adenocarcinoma in mult. adenomatous polypsosis coli |
| 8230/2: Duct carcinoma in situ, solid type |
| 8230/3: Solid carcinoma, NOS |
| 8231/3: Carcinoma simplex |
| 8240/2: Carcinoid tumor, in situ |
| 8240/3: Carcinoid tumor, malignant |
| 8241/2 |
| 8241/3: Enterochromaffin cell carcinoid |
| 8242/0 |
| 8242/3: Enterochromaffin-like cell tumor, malignant |
| 8243/2 |
| 8243/3: Goblet cell carcinoid |
| 8244/3: Composite carcinoid |
| 8245/2 |
| 8245/3: Adenocarcinoid tumor |
| 8246/2: Neuroendocrine carcinoma in situ |
| 8246/3: Neuroendocrine carcinoma |
| 8247/2: Merkel cell carcinoma in situ |
| 8247/3: Merkel cell carcinoma |
| 8248/3: Apudoma |
| 8249/3: Atypical carcinoid tumor |
| 8250/2: Bronchiolo-alveolar adenocarcinoma in situ |
| 8250/3: Bronchiolo-alveolar adenocarcinoma |
| 8251/3: Alveolar adenocarcinoma |
| 8252/2: Bronchiolo-alveolar carcinoma, non-mucinous, in situ |
| 8252/3: Bronchiolo-alveolar carcinoma, non-mucinous |
| 8253/2: Bronchiolo-alveolar carcinoma, mucinous, in situ |
| 8253/3: Bronchiolo-alveolar carcinoma, mucinous |
| 8254/3: Bronchiolo-alveolar ca., mucinous & non-mucinous |
| 8255/2: Adenocarcinoma in situ with mixed subtypes |
| 8255/3: Adenocarcinoma with mixed subtypes |
| 8260/0: Papillary adenoma, NOS |
| 8260/1 |
| 8260/2: Papillary adenocarcinoma in situ, NOS |
| 8260/3: Papillary adenocarcinoma, NOS |
| 8261/2: Adenocarcinoma in situ in villous adenoma |
| 8261/3: Adenocarcinoma in villous adenoma |
| 8262/2: Villous adenocarcinoma in situ |
| 8262/3: Villous adenocarcinoma |
| 8263/2: Adenocarcinoma in situ in tubulovillous adenoma |
| 8263/3: Adenocarcinoma in tubulovillous adenoma |
| 8264/3 |
| 8270/0: Chromophobe adenoma |
| 8270/1: Chromophobe adenoma, borderline |
| 8270/2 |
| 8270/3: Chromophobe carcinoma |
| 8271/0: Prolactinoma |
| 8271/1 |
| 8271/3: Prolactinoma, malignant |
| 8272/0: Pituitary adenoma, NOS |
| 8272/1: Pituitary, borderline malignancy |
| 8272/3: Pituitary carcinoma, NOS |
| 8280/0: Acidophil adenoma |
| 8280/3: Acidophil carcinoma |
| 8281/0: Mixed acidophil-basophil adenoma |
| 8290/0: Oxyphilic adenoma |
| 8290/2: Oxyphilic adenocarcinoma in situ |
| 8290/3: Oxyphilic adenocarcinoma |
| 8300/0: Basophil adenoma |
| 8300/3: Basophil carcinoma |
| 8310/0 |
| 8310/2: Clear cell adenocarcinoma in situ |
| 8310/3: Clear cell adenocarcinoma, NOS |
| 8312/2: Renal cell carcinoma in situ, NOS |
| 8312/3: Renal cell carcinoma |
| 8313/3: Clear cell adenocarcinofibroma |
| 8314/3: Lipid-rich carcinoma |
| 8315/2 |
| 8315/3: Glycogen-rich carcinoma |
| 8316/2: Cyst-associated renal cell carcinoma in situ |
| 8316/3: Cyst-associated renal cell carcinoma |
| 8317/3: Renal cell carcinoma, chromophobe type |
| 8318/3: Renal cell carcinoma, sarcomatoid |
| 8319/2 |
| 8319/3: Collecting duct carcinoma |
| 8320/2 |
| 8320/3: Granular cell carcinoma |
| 8321/3 |
| 8322/3: Water-clear cell adenocarcinoma |
| 8323/0: Mixed cell adenoma |
| 8323/2: Mixed cell adenocarcinoma in situ |
| 8323/3: Mixed cell adenocarcinoma |
| 8325/3: Metanephric adenomacarcinoma |
| 8330/2: Follicular adenocarcinoma in situ |
| 8330/3: Follicular adenocarcinoma, NOS |
| 8331/3: Follicular adenocarcinoma well differentiated |
| 8332/3: Follicular adenocarcinoma trabecular |
| 8333/3: Fetal adenocarcinoma |
| 8334/0 |
| 8335/2: Macrofollicular carcinoma in situ |
| 8335/3: Follicular carcinoma, minimally invasive |
| 8336/3 |
| 8337/3: Insular carcinoma |
| 8340/2: Papillary carcinoma in situ, follicular variant |
| 8340/3: Papillary carcinoma, follicular variant |
| 8341/0 |
| 8341/2: Papillary microcarcinoma in situ |
| 8341/3: Papillary microcarcinoma |
| 8342/3: Papillary carcinoma, oxyphilic cell |
| 8343/2: Papillary carcinoma, encapsulated, in situ |
| 8343/3: Papillary carcinoma, encapsulated |
| 8344/2 |
| 8344/3: Papillary carcinoma, columnar cell |
| 8345/3: Medullary carcinoma with amyloid stroma |
| 8346/3: Mixed medullary-follicular carcinoma |
| 8347/3: Mixed medullary-papillary carcinoma |
| 8350/3: Nonencapsulated sclerosing carcinoma |
| 8360/1: Multiple endocrine adenomas |
| 8360/3 |
| 8361/3 |
| 8370/0 |
| 8370/2: Adrenal cortical carcinoma in situ |
| 8370/3: Adrenal cortical carcinoma |
| 8372/0 |
| 8380/2: Endometrioid adenocarcinoma in situ |
| 8380/3: Endometrioid carcinoma |
| 8381/2 |
| 8381/3: Endometrioid adenofibroma, malignant |
| 8382/2: Endometrioid adenoca in situ, secretory variant |
| 8382/3: Endometrioid adenocarcinoma, secretory variant |
| 8383/3: Endometrioid adenocarcinoma, ciliated cell variant |
| 8384/2: Adenocarcinoma, endocervical type, in situ |
| 8384/3: Adenocarcinoma, endocervical type |
| 8390/2: Skin appendage carcinoma in situ |
| 8390/3: Skin appendage carcinoma |
| 8392/3: Syringofibroadenocarcinoma |
| 8400/2: Sweat gland adenocarcinoma in situ |
| 8400/3: Sweat gland adenocarcinoma |
| 8401/2: Apocrine adenocarcinoma in situ |
| 8401/3: Apocrine adenocarcinoma |
| 8402/2: Nodular hidradenoma, in situ |
| 8402/3: Nodular hidradenoma, malignant |
| 8403/3: Malignant eccrine spiradenoma |
| 8405/3: Papillary hidradenocarcinoma |
| 8406/3: Papillary syringadenocarcinoma |
| 8407/2 |
| 8407/3: Sclerosing sweat duct carcinoma |
| 8408/3: Eccrine papillary adenocarcinoma |
| 8409/2: Eccrine poroma, in situ |
| 8409/3: Eccrine poroma, malignant |
| 8410/2: Sebaceous adenocarcinoma in situ |
| 8410/3: Sebaceous adenocarcinoma |
| 8413/2: Eccrine adenocarcinoma, in situ |
| 8413/3: Eccrine adenocarcinoma |
| 8420/2 |
| 8420/3: Ceruminous adenocarcinoma |
| 8430/2: Mucoepidermoid carcinoma in situ |
| 8430/3: Mucoepidermoid carcinoma |
| 8440/0 |
| 8440/2: Cystadenocarcinoma in situ |
| 8440/3: Cystadenocarcinoma, NOS |
| 8441/0 |
| 8441/2: Serous cystadenocarcinoma in situ, NOS |
| 8441/3: Serous cystadenocarcinoma, NOS |
| 8442/1: Serous cystadenoma, borderline malignancy |
| 8442/2: Serous cystadenocarcinoma in situ |
| 8442/3: Proliferating serous carcinoma |
| 8443/3: Clear cell cystadenocarcinoma |
| 8444/3: Clear cell cystic tumor, malignant |
| 8450/2: Papillary cystadenocarcinoma in situ, NOS |
| 8450/3: Papillary cystadenocarcinoma, NOS |
| 8451/1: Papillary cystadenoma, borderline malignancy |
| 8451/3 |
| 8452/0 |
| 8452/1 |
| 8452/2 |
| 8452/3: Solid pseudopapillary carcinoma |
| 8453/2: Intraductal papillary-mucinous ca., non-invasive |
| 8453/3: Intraductal papillary-mucinous carcinoma, invasive |
| 8460/2: Papillary serous cystadenoca in situ, NOS |
| 8460/3: Papillary serous cystadenocarcinoma |
| 8461/2: Serous surface papillary carcinoma, in situ |
| 8461/3: Serous surface papillary carcinoma |
| 8462/1: Serous papillary cystic tumor, boderline maligancy |
| 8462/2: Serous papillary cystadenocarcinoma in situ |
| 8462/3: Papillary serous cystadenocarcinoma |
| 8463/3: Serous surface papillary carcinoma |
| 8470/2: Mucinous cystadenocarcinoma, non-invasive |
| 8470/3: Mucinous cystadenocarcinoma, NOS |
| 8471/2: Papillary mucinous cystadenoca situ, NOS |
| 8471/3: Papillary mucinous cystadenocarcinoma |
| 8472/1: Mucinous cystic tumor of borderline malignancy |
| 8472/2: Mucinous cystic adenocarcinoma in situ |
| 8472/3: Mucinous cystadenocarcinoma |
| 8473/1: Papillary mucinous cystadenoma, borderline malig. |
| 8473/2: Papillary mucinous cystadenocarcinoma, in situ |
| 8473/3: Papillary pseudomucinous cystadenocarcinoma |
| 8480/2: Mucinous adenocarcinoma in situ |
| 8480/3: Mucinous adenocarcinoma |
| 8481/2: Mucin-producing adenocarcinoma in situ |
| 8481/3: Mucin-producing adenocarcinoma |
| 8482/3: Mucinous adenocarcinoma, endocervical type |
| 8490/0: Signet ring cell tumor, benign |
| 8490/2: Signet ring cell carcinoma in situ |
| 8490/3: Signet ring cell carcinoma |
| 8500/2: Intraductal carcinoma, noninfiltrating, NOS |
| 8500/3: Infiltrating duct carcinoma, NOS |
| 8501/2: Comedocarcinoma, non-infiltrating |
| 8501/3: Comedocarcinoma, NOS |
| 8502/2: Secretory carcinoma in situ of breast |
| 8502/3: Secretory carcinoma of breast |
| 8503/2: Noninfiltrating intraductal papillary adenocarcinoma |
| 8503/3: Intraductal papillary adenocarcinoma with invasion |
| 8504/2: Noninfiltrating intracystic carcinoma |
| 8504/3: Intracystic carcinoma, NOS |
| 8507/2: Intraductal micropapillary carcinoma |
| 8507/3: Ductal carcinoma, micropapillary |
| 8508/2: Cystic hypersecretory carcinoma in situ |
| 8508/3: Cystic hypersecretory carcinoma |
| 8510/2: Medullary carcinoma in situ, NOS |
| 8510/3: Medullary carcinoma, NOS |
| 8512/2: Medullary carcinoma in situ with lymphoid stroma |
| 8512/3: Medullary carcinoma with lymphoid stroma |
| 8513/2 |
| 8513/3: Atypical medullary carcinoma |
| 8514/2 |
| 8514/3: Duct carcinoma, desmoplastic type |
| 8520/2: Lobular carcinoma in situ |
| 8520/3: Lobular carcinoma, NOS |
| 8521/2: Ductular carcinoma in situ |
| 8521/3: Infiltrating ductular carcinoma |
| 8522/2: Intraductal and lobular in situ carcinoma |
| 8522/3: Infiltrating duct and lobular carcinoma |
| 8523/2: Intraductal with other types of carcinoma in situ |
| 8523/3: Infiltrating duct mixed with other types of ca. |
| 8524/2: Lobular CIS with other CIS |
| 8524/3: Infiltrating lobular mixed with other types of ca. |
| 8525/2 |
| 8525/3: Polymorphous low grade adenocarcinoma |
| 8530/3: Inflammatory carcinoma |
| 8540/2: Paget disease, mammary, in situ |
| 8540/3: Paget disease, mammary |
| 8541/2: Paget disease in situ and intraductal carcinoma |
| 8541/3: Paget disease and infiltrating duct carcinoma |
| 8542/2: Paget disease in situ, extra mammary (except bone) |
| 8542/3: Paget disease, extramammary |
| 8543/2: Paget disease in situ and intraductal carcinoma |
| 8543/3: Paget disease and intraductal carcinoma |
| 8550/2: Acinar cell carcinoma in situ |
| 8550/3: Acinar cell carcinoma |
| 8551/3: Acinar cell cystadenocarcinoma |
| 8560/2: Squamous cell CIS and glandular papilloma |
| 8560/3: Adenosquamous carcinoma |
| 8561/0 |
| 8561/3: Warthin tumor, malignant |
| 8562/2: Epithelial-myoepithelial carcinoma in situ |
| 8562/3: Epithelial-myoepithelial carcinoma |
| 8570/2: Adenocarcinoma in situ with squamous metaplasia |
| 8570/3: Adenocarcinoma with squamous metaplasia |
| 8571/3: Adenocarcinoma w. cartilaginous & osseous metaplasia |
| 8572/0: Adenoma with spindle cell metaplasia |
| 8572/3: Adenocarcinoma with spindle cell metaplasia |
| 8573/2: Adenocarcinoma in situ with apocrine metaplasia |
| 8573/3: Adenocarcinoma with apocrine metaplasia |
| 8574/2: Adenocarcinoma in situ with neuroendocrine differentiation |
| 8574/3: Adenocarcinoma with neuroendocrine differentiation |
| 8575/2 |
| 8575/3: Metaplastic carcinoma, NOS |
| 8576/3: Hepatoid adenocarcinoma |
| 8580/2: Thymoma, in situ, NOS |
| 8580/3: Thymoma, malignant, NOS |
| 8581/2 |
| 8581/3: Thymoma, type A, malignant |
| 8582/2 |
| 8582/3: Thymoma, type AB, malignant |
| 8583/3: Thymoma, type B1, malignant |
| 8584/2 |
| 8584/3: Thymoma, type B2, malignant |
| 8585/3: Thymoma, type B3, malignant |
| 8586/3: Thymic carcinoma, NOS |
| 8588/3: Spindle epithelial tumor with thymus-like element |
| 8589/3: Carcinoma showing thymus-like element |
| 8590/3: Sex cord-gonadal stromal tumor, malignant, NOS |
| 8591/3 |
| 8592/3 |
| 8593/3: Malignant Stromal tumor, with sex cord elements |
| 8600/3: Thecoma, malignant |
| 8602/3: Sclerosing stromal tumor, malignant |
| 8620/2 |
| 8620/3: Granulosa cell tumor, malignant |
| 8621/3: Granulosa cell-theca cell tumor, malignant |
| 8622/3: Juvenile granulosa cell tumor, malignant |
| 8623/3: Sex cord tumor with annular tubules, malignant |
| 8630/3: Androblastoma, malignant |
| 8631/3: Sertoli-Leydig cell tumor, poorly differentiated |
| 8632/3: Gynandroblastoma, malignant |
| 8633/3 |
| 8634/3: Sertoli-Leydig, poor diff. w. heterologous elements |
| 8640/2 |
| 8640/3: Sertoli cell carcinoma |
| 8642/3 |
| 8650/2 |
| 8650/3: Leydig cell tumor, malignant |
| 8670/2 |
| 8670/3: Steroid cell tumor, malignant |
| 8680/0: Paraganglioma, benign |
| 8680/1: Paraganglioma, NOS |
| 8680/3: Paraganglioma, malignant |
| 8682/1 |
| 8683/0 |
| 8683/1 |
| 8683/3: Gangliocytic paraganglioma, malignant |
| 8690/0 |
| 8690/1: Glomus jugulare tumor, NOS |
| 8690/3: Glomus jugulare tumor, malignant |
| 8692/3: Carotid body tumor, malignant |
| 8693/1: Extra-adrenal paraganglioma, NOS |
| 8693/3: Extra-adrenal paraganglioma, malignant |
| 8700/0 |
| 8700/3: Pheochromocytoma |
| 8710/2 |
| 8710/3: Glomangiosarcoma |
| 8711/0: Glomus tumor, NOS |
| 8711/3: Glomus tumor, malignant |
| 8712/0 |
| 8713/0 |
| 8713/3 |
| 8720/0: Pigmented nevus, NOS |
| 8720/2: Melanoma in situ |
| 8720/3: Malignant melanoma, NOS |
| 8721/2: Nodular melanoma, in situ |
| 8721/3: Nodular melanoma |
| 8722/2: Balloon cell melanoma, in situ |
| 8722/3: Balloon cell melanoma |
| 8723/2: Melanoma in situ, regressing |
| 8723/3: Malignant melanoma, regressing |
| 8726/0: Magnocellular nevus |
| 8726/1 |
| 8726/3: Malignant melanoma in magnocellular nevus |
| 8727/3: Dysplastic nevus, malignant |
| 8728/0 |
| 8728/1: Meningeal melanocytoma |
| 8728/2 |
| 8728/3: Meningeal melanomatosis |
| 8730/2: Amelanotic melanoma, in situ |
| 8730/3: Amelanotic melanoma |
| 8740/2: Melanoma in situ in junctional nevus |
| 8740/3: Malignant melanoma in junctional nevus |
| 8741/2: Precancerous melanosis, NOS |
| 8741/3: Malignant melanoma in precancerous melanosis |
| 8742/2: Lentigo maligna |
| 8742/3: Lentigo maligna melanoma |
| 8743/2: Superficial spreading melanoma, in situ |
| 8743/3: Superficial spreading melanoma |
| 8744/2: Acral lentiginous melanoma, in situ |
| 8744/3: Acral lentiginous melanoma, malignant |
| 8745/2: Desmoplastic melanoma, in situ |
| 8745/3: Desmoplastic melanoma, malignant |
| 8746/2: Mucosal lentiginous melanoma in situ |
| 8746/3: Mucosal lentiginous melanoma |
| 8750/2 |
| 8750/3 |
| 8760/2: Melanoma in situ in compound nevus |
| 8760/3: Malignant melanoma in compound nevus |
| 8761/2: Melanoma in situ in giant pigmented nevus |
| 8761/3: Malignant melanoma in giant pigmented nevus |
| 8770/2: Epithelioid and spindle cell melanoma in situ |
| 8770/3: Mixed epithelioid and spindle cell melanoma |
| 8771/2: Epithelioid cell melanoma in situ |
| 8771/3: Epithelioid cell melanoma |
| 8772/0 |
| 8772/2: Spindle cell melanoma in situ, NOS |
| 8772/3: Spindle cell melanoma, NOS |
| 8773/3: Spindle cell melanoma, type A |
| 8774/2 |
| 8774/3: Spindle cell melanoma, type B |
| 8780/2 |
| 8780/3: Blue nevus, malignant |
| 8790/3: Cellular blue nevus, malignant |
| 8800/0: Soft tissue tumor, benign |
| 8800/3: Sarcoma, NOS |
| 8801/3: Spindle cell sarcoma |
| 8802/3: Giant cell sarcoma |
| 8803/3: Small cell sarcoma |
| 8804/3: Epithelioid sarcoma |
| 8805/3: Undifferentiated sarcoma |
| 8806/3: Desmoplastic small round cell tumor |
| 8810/0: Fibroma, NOS |
| 8810/3: Fibrosarcoma, NOS |
| 8811/1 |
| 8811/3: Fibromyxosarcoma |
| 8812/3: Periosteal fibrosarcoma |
| 8813/3: Fascial fibrosarcoma |
| 8814/3: Infantile fibrosarcoma |
| 8815/0: Solitary fibrous tumor |
| 8815/1 |
| 8815/3: Solitary fibrous tumor, malignant |
| 8820/0: Elastofibroma |
| 8821/1: Aggressive firbomatosis |
| 8821/3: Aggressive fibromatosis, malignant |
| 8822/2 |
| 8822/3: Abdominal fibromatosis, malignant |
| 8823/3: Desmoplastic fibrosarcoma |
| 8824/0 |
| 8824/1 |
| 8824/3: Myofibroma, malignant |
| 8825/0: Myofibroblastoma |
| 8825/1: Myofibroblastic tumor, NOS |
| 8825/2 |
| 8825/3: Myofibroblastoma, malignant |
| 8826/3: Angiomyofibroblastoma, malignant |
| 8830/0: Fibrous histiocytoma, benign |
| 8830/1 |
| 8830/3: Fibrous histiocytoma, malignant |
| 8831/0 |
| 8831/3: Histiocytoma, NOS, malignant |
| 8832/3: Dermatofibrosarcoma, NOS |
| 8833/3: Pigmented dermatofibrosarcoma protuberans |
| 8835/1 |
| 8835/3: Malignant plexiform fibrohistiocytic tumor |
| 8836/1 |
| 8836/3: Malignant angiomatoid fibrous histiocytoma |
| 8840/0 |
| 8840/3: Myxosarcoma |
| 8841/1 |
| 8841/3: Angiomyxoma, malignant |
| 8842/0 |
| 8842/3: Ossifying fibromyxoid tumor, malignant |
| 8850/0: Lipoma, NOS |
| 8850/1: Atypical lipoma |
| 8850/3: Liposarcoma, NOS |
| 8851/0: Fibrolipoma |
| 8851/3: Liposarcoma, well differentiated |
| 8852/3: Myxoid liposarcoma |
| 8853/3: Round cell liposarcoma |
| 8854/0 |
| 8854/3: Pleomorphic liposarcoma |
| 8855/3: Mixed type liposarcoma |
| 8856/0: Intramuscular lipoma |
| 8856/3 |
| 8857/0 |
| 8857/3: Fibroblastic liposarcoma |
| 8858/3: Dedifferentiated liposarcoma |
| 8860/3: Angiomyoliposarcoma |
| 8861/0: Angiolipoma, NOS |
| 8861/3 |
| 8870/0 |
| 8870/3 |
| 8880/3 |
| 8881/1 |
| 8890/0: Leiomyoma, NOS |
| 8890/3: Leiomyosarcoma, NOS |
| 8891/3: Epithelioid leiomyosarcoma |
| 8892/3 |
| 8893/3: Bizarre leiomyosarcoma |
| 8894/0: Angiomyoma |
| 8894/3: Angiomyosarcoma |
| 8895/3: Myosarcoma |
| 8896/3: Myxoid leiomyosarcoma |
| 8897/1: Smooth muscle tumor, NOS |
| 8897/3: Malignant tumor of smooth muscle |
| 8900/0: Rhabdomyoma, NOS |
| 8900/3: Rhabdomyosarcoma, NOS |
| 8901/3: Pleomorphic rhabdomyosarcoma, adult type |
| 8902/3: Mixed type rhabdomyosarcoma |
| 8904/0 |
| 8910/3: Embryonal rhabdomyosarcoma |
| 8912/3: Spindle cell rhabdomyosarcoma |
| 8920/3: Alveolar rhabdomyosarcoma |
| 8921/3: Rhabdomyosarcoma with ganglionic differentiation |
| 8930/3: Endometrial stromal sarcoma |
| 8931/3: Endometrial stromal sarcoma, low grade |
| 8932/3 |
| 8933/2 |
| 8933/3: Adenosarcoma |
| 8934/3: Carcinofibroma |
| 8935/0: Stromal tumor, benign |
| 8935/3: Stromal sarcoma, NOS |
| 8936/2: Gastrointestinal stromal tumor, NOS, in situ |
| 8936/3: Gastrointestinal stromal sarcoma |
| 8940/0: Pleomorphic adenoma |
| 8940/2 |
| 8940/3: Mixed tumor, malignant, NOS |
| 8941/2: Carcinoma in situ in pleomorphic adenoma |
| 8941/3: Carcinoma in pleomorphic adenoma |
| 8950/3: Mullerian mixed tumor |
| 8951/3: Mesodermal mixed tumor |
| 8959/3: Malignant cystic nephroma |
| 8960/1 |
| 8960/3: Nephroblastoma, NOS |
| 8963/3: Malignant rhabdoid tumor |
| 8964/3: Clear cell sarcoma of kidney |
| 8970/3: Hepatoblastoma |
| 8971/3: Pancreatoblastoma |
| 8972/3: Pulmonary blastoma |
| 8973/3: Pleuropulmonary blastoma |
| 8974/3 |
| 8980/3: Carcinosarcoma, NOS |
| 8981/3: Carcinosarcoma, embryonal type |
| 8982/0 |
| 8982/2 |
| 8982/3: Malignant myoepithelioma |
| 8983/2: Adenomyoepithelioma, in situ |
| 8983/3: Adenomyoepithelioma, malignant |
| 8990/0: Mesenchymoma, benign |
| 8990/1: Mesenchymoma, NOS |
| 8990/3: Mesenchymoma, malignant |
| 8991/3: Embryonal sarcoma |
| 9000/0: Brenner tumor, NOS |
| 9000/3: Brenner tumor, malignant |
| 9013/3: Adenofibroma, malignant |
| 9014/2: Serous adenocarcinofibroma, in situ |
| 9014/3: Serous adenocarcinofibroma |
| 9015/3: Mucinous adenocarcinofibroma |
| 9020/1: Phyllodes tumor, borderline |
| 9020/2 |
| 9020/3: Phyllodes tumor, malignant |
| 9040/0 |
| 9040/3: Synovial sarcoma, NOS |
| 9041/3: Synovial sarcoma, spindle cell |
| 9042/3: Synovial sarcoma, epithelioid cell |
| 9043/3: Synovial sarcoma, biphasic |
| 9044/3: Clear cell sarcoma, NOS (except of kidney M-8964/3) |
| 9050/3: Mesothelioma, malignant |
| 9051/0 |
| 9051/3: Fibrous mesothelioma, malignant |
| 9052/3: Epithelioid mesothelioma, malignant |
| 9053/3: Mesothelioma, biphasic, malignant |
| 9055/3: Multicystic mesothelioma, malignant |
| 9060/3: Dysgerminoma |
| 9061/2: Seminoma, in situ |
| 9061/3: Seminoma, NOS |
| 9062/3: Seminoma, anaplastic |
| 9063/2: Spermatocytic seminoma, in situ |
| 9063/3: Spermatocytic seminoma |
| 9064/0 |
| 9064/1 |
| 9064/2: Intratubular malignant germ cells |
| 9064/3: Germinoma |
| 9065/0 |
| 9065/2 |
| 9065/3: Germ cell tumor, nonseminomatous |
| 9070/2: Embryonal carcinoma, NOS, in situ |
| 9070/3: Embryonal carcinoma, NOS |
| 9071/2 |
| 9071/3: Yolk sac tumor |
| 9072/3: Polyembryoma |
| 9073/3: Gonadoblastoma, malignant |
| 9080/0: Teratoma, benign |
| 9080/1: Teratoma, NOS |
| 9080/2: Teratoma, in situ |
| 9080/3: Teratoma, malignant, NOS |
| 9081/3: Teratocarcinoma |
| 9082/3: Malignant teratoma, undifferentiated |
| 9083/3: Malignant teratoma, intermediate |
| 9084/0: Dermoid cyst, NOS |
| 9084/1 |
| 9084/3: Teratoma with malignant transformation |
| 9085/2: Mixed germ cell tumor, in situ |
| 9085/3: Mixed germ cell tumor |
| 9090/3: Struma ovarii, malignant |
| 9091/3: Strumal carcinoid, malignant |
| 9100/2: Choriocarcinoma in situ, NOS |
| 9100/3: Choriocarcinoma |
| 9101/2: Choriocarcinoma combined w. other germ cell elements, in situ |
| 9101/3: Choriocarcinoma combined w. other germ cell elements |
| 9102/2 |
| 9102/3: Malignant teratoma, trophoblastic |
| 9103/3: Partial hydatidiform mole, malignant |
| 9104/3: Malignant placental site trophoblastic tumor |
| 9105/3: Trophoblastic tumor, epithelioid |
| 9110/2 |
| 9110/3: Mesonephroma, malignant |
| 9120/0: Hemangioma, NOS |
| 9120/1: Hemangioma, NOS, borderline |
| 9120/3: Hemangiosarcoma |
| 9121/0: Cavernous hemangioma |
| 9121/1: Cavernous hemangioma, borderline |
| 9121/3 |
| 9122/0: Venous hemangioma |
| 9122/1 |
| 9123/0: Racemose hemangioma |
| 9124/3: Kupffer cell sarcoma |
| 9125/0: Epithelioid hemangioma |
| 9125/3: Epithelioid hemangiosarcoma |
| 9130/0: Hemangioendothelioma, benign |
| 9130/1: Hemangioendothelioma, NOS |
| 9130/3: Hemangioendothelioma, malignant |
| 9131/0: Capillary hemangioma |
| 9131/3 |
| 9133/1: Epithelioid hemangioendothelioma, NOS |
| 9133/3: Epithelioid hemangioendothelioma, malignant |
| 9135/1 |
| 9136/1: Spindle cell hemangioendothelioma |
| 9136/3 |
| 9140/3: Kaposi sarcoma |
| 9150/0: Hemangiopericytoma, benign |
| 9150/1: Hemangiopericytoma, NOS |
| 9150/3: Hemangiopericytoma, malignant |
| 9160/0: Angiofibroma, NOS |
| 9160/3: Angiofibrosarcoma |
| 9161/0: Acquired tufted hemangioma |
| 9161/1: Hemangioblastoma |
| 9161/3: Hemangioblastoma, malignant |
| 9170/0: Lymphangioma, NOS |
| 9170/3: Lymphangiosarcoma |
| 9171/3 |
| 9172/0 |
| 9173/0: Cystic lymphangioma |
| 9173/3 |
| 9174/3 |
| 9175/3 |
| 9180/0: Osteoma, NOS |
| 9180/3: Osteosarcoma, NOS |
| 9181/3: Chondroblastic osteosarcoma |
| 9182/3: Fibroblastic osteosarcoma |
| 9183/3: Telangiectatic osteosarcoma |
| 9184/3: Osteosarcoma in Paget disease |
| 9185/3: Small cell osteosarcoma |
| 9186/3: Central osteosarcoma |
| 9187/3: Instrosseous well differentiated osteosarcoma |
| 9191/0 |
| 9192/3: Parosteal osteosarcoma |
| 9193/3: Periosteal osteosarcoma |
| 9194/3: High grade surface osteosarcoma |
| 9195/3 |
| 9200/0 |
| 9200/1 |
| 9200/3: Malignant, osteosarcoma |
| 9210/0 |
| 9210/1 |
| 9220/0: Chondroma, NOS |
| 9220/1 |
| 9220/3: Chondrosarcoma, NOS |
| 9221/3: Juxtacortical chondrosarcoma |
| 9230/3: Chondroblastoma, malignant |
| 9231/3: Myxoid chondrosarcoma |
| 9240/3: Mesenchymal chondrosarcoma |
| 9241/0 |
| 9241/3 |
| 9242/3: Clear cell chondrosarcoma |
| 9243/3: Dedifferentiated chondrosarcoma |
| 9250/1: Giant cell tumor of bone, NOS |
| 9250/3: Giant cell tumor of bone, malignant |
| 9251/1 |
| 9251/3: Malignant giant cell tumor of soft parts |
| 9252/0: Tenosynovial giant cell tumor |
| 9252/3: Malignant tenosynovial giant cell tumor |
| 9260/3: Ewing sarcoma |
| 9261/3: Adamantinoma of long bones |
| 9262/0 |
| 9270/3: Odontogenic tumor, malignant |
| 9282/3: Complex odontosarcoma |
| 9290/3: Ameloblastic odontosarcoma |
| 9300/0 |
| 9302/3 |
| 9310/3: Ameloblastoma, malignant |
| 9312/3: Squamous odontogenic tumor, malignant |
| 9321/3: Central odontogenic fibrosarcoma |
| 9330/3: Ameloblastic fibrosarcoma |
| 9340/3 |
| 9341/3 |
| 9342/3: Odontogenic carcinosarcoma |
| 9350/0: Craniopharyngioma, benign |
| 9350/1: Craniopharyngioma |
| 9350/3: Craniopharyngiom, malignant |
| 9351/0: Craniopharyngioma, adamantinomatous, benign |
| 9351/1: Adamantinomatous craniopharyngioma |
| 9351/3: Malignant craniopharyngioma, adamantinomatous |
| 9352/0: Papillary craniopharyngioma, benign |
| 9352/1: Papillary craniopharyngioma |
| 9360/0: Pinealoma, benign |
| 9360/1: Pinealoma, NOS |
| 9361/0: Pineocytoma, benign |
| 9361/1: Pineocytoma |
| 9361/3: Pineocytoma, malignant |
| 9362/0 |
| 9362/1 |
| 9362/3: Pineoblastoma |
| 9363/3: Melanotic neuroectodermal tumor, malignant |
| 9364/3: Peripheral neuroectodermal tumor |
| 9365/3: Askin tumor |
| 9370/0 |
| 9370/1: Chordoma, borderline malignancy |
| 9370/3: Chordoma, NOS |
| 9371/3: Chondroid chordoma |
| 9372/3: Dedifferentiated chordoma |
| 9373/3 |
| 9380/0: Glioma, benign |
| 9380/1: Glioma, borderline |
| 9380/3: Glioma, malignant |
| 9381/0: Gliomatosis cerebri, benign |
| 9381/1 |
| 9381/3: Gliomatosis cerebri |
| 9382/0: Mixed glioma, benign |
| 9382/3: Mixed glioma |
| 9383/0: Subependymoma, benign |
| 9383/1: Subependymoma |
| 9383/3: Subependymoma, malignant |
| 9384/0: Supependymal giant cell astrocytoma, benign |
| 9384/1: Supependymal giant cell astrocytoma |
| 9384/3: Subependymal giant cell astrocytoma, malignant |
| 9390/0: Choroid plexus papilloma, NOS |
| 9390/1: Atypical choroid plexus papilloma |
| 9390/3: Choroid plexus papilloma, malignant |
| 9391/0: Ependymoma, benign |
| 9391/1: Ependymoma, borderline |
| 9391/3: Ependymoma, NOS |
| 9392/3: Ependymoma, anaplastic |
| 9393/0: Papillary ependymoma, benign |
| 9393/1 |
| 9393/3: Papillary ependymoma, NOS |
| 9394/0: Myxopapillary ependymoma, benign |
| 9394/1: Myxopapillary ependymoma |
| 9394/3: Myxopapillary ependymoma, malignant |
| 9400/0: Astrocytoma, benign |
| 9400/1: Astrocytoma, borderline malignancy |
| 9400/3: Astrocytoma, NOS |
| 9401/0: Astrocytoma, anaplastic, benign |
| 9401/3: Astrocytoma, anaplastic |
| 9410/3: Protoplasmic astrocytoma |
| 9411/0: Gemistocytic astrocytoma, benign |
| 9411/3: Gemistocytic astrocytoma |
| 9412/0: Desmoplastic infantile astrocytoma, benign |
| 9412/1: Desmoplastic infantile astrocytoma |
| 9412/3 |
| 9413/0: Dysembryoplastic neuroepithelial tumor |
| 9413/1: Dysembryoplastic neuroepithelial tumor, borderline |
| 9413/3: Dysembryoplastic neuroepithelial tumor, malignant |
| 9420/0 |
| 9420/3: Fibrillary astrocytoma |
| 9421/3: Pilocytic astrocytoma, malignant |
| 9423/3: Polar spongioblastoma |
| 9424/0 |
| 9424/3: Pleomorphic xanthoastrocytoma |
| 9430/0 |
| 9430/3: Astroblastoma |
| 9440/0: Glioblastoma, benign |
| 9440/1: Glioblastoma, NOS, borderline |
| 9440/3: Glioblastoma, NOS |
| 9441/3: Giant cell glioblastoma |
| 9442/1: Gliofibroma |
| 9442/3: Gliosarcoma |
| 9444/0 |
| 9444/1: Chordoid glioma |
| 9444/3 |
| 9450/0: Oligodendroglioma, NOS, benign |
| 9450/1: Oligodendroglioma, NOS, borderline |
| 9450/3: Oligodendroglioma, NOS |
| 9451/0 |
| 9451/1 |
| 9451/3: Oligodendroglioma, anaplastic |
| 9460/0 |
| 9460/3: Oligodendroblastoma |
| 9470/0 |
| 9470/3: Medulloblastoma, NOS |
| 9471/3: Desmoplastic medulloblastoma |
| 9472/3: Medullomyoblastoma |
| 9473/0 |
| 9473/3: Primitive neuroectodermal tumor |
| 9474/3: Large cell medulloblastoma |
| 9480/3: Cerebellar sarcoma, NOS |
| 9490/0: Ganglioneuroma |
| 9490/1: Ganglioneuroma, borderline |
| 9490/3: Ganglioneuroblastoma |
| 9492/0: Gangliocytoma |
| 9492/1 |
| 9493/0: Dysplastic gangliocytoma of cerebellum |
| 9500/0: Neuroblastoma, NOS, benign |
| 9500/2: Neuroblastoma, in situ, NOS |
| 9500/3: Neuroblastoma, NOS |
| 9501/3: Medulloepithelioma, NOS |
| 9502/3: Teratoid medulloepithelioma |
| 9503/0 |
| 9503/3: Neuroepithelioma, NOS |
| 9504/3 |
| 9505/0: Ganglioglioma, benign |
| 9505/1: Ganglioglioma, NOS |
| 9505/3: Ganglioglioma, anaplastic |
| 9506/0: Central neurocytoma, benign |
| 9506/1: Central neurocytoma |
| 9506/3: Neurocytoma, malignant |
| 9508/3: Atypical teratoid/rhabdoid tumor |
| 9510/3: Retinoblastoma, NOS |
| 9511/3: Retinoblastoma, differentiated |
| 9512/3: Retinoblastoma, undifferentiated |
| 9513/3: Retinoblastoma, diffuse |
| 9520/0 |
| 9520/3: Olfactory neurogenic tumor |
| 9521/3: Olfactory neurcytoma |
| 9522/3: Olfactory neuroblastoma |
| 9523/3: Olfactory neuroepithelioma |
| 9530/0: Meningioma, NOS |
| 9530/1: Meningiomatosis, NOS |
| 9530/3: Meningioma, malignant |
| 9531/0: Meningothelial meningioma |
| 9531/1: Meningiothelial meningioma, borderline |
| 9531/3: Meningiothelial meningioma, malignant |
| 9532/0: Fibrous meningioma |
| 9532/1 |
| 9532/3: Fibrous meningioma, malignant |
| 9533/0: Psammomatous meningioma |
| 9533/1 |
| 9533/3: Psammomatous meningioma, malignant |
| 9534/0: Angiomatous meningioma |
| 9534/1 |
| 9534/3: Angiomatous meningioma, malignant |
| 9535/0: Hemangioblastic meningioma |
| 9535/3: Hemangioblastic meningioma, malignant |
| 9537/0: Transitional meningioma |
| 9537/1 |
| 9537/3: Transitional meningioma, malignant |
| 9538/0: Clear cell meningioma, benign |
| 9538/1: Clear cell meningioma |
| 9538/3: Papillary meningioma |
| 9539/0: Atypical meningioma, benign |
| 9539/1: Atypical meningioma, NOS |
| 9539/3: Meningeal sarcomatosis |
| 9540/0: Neurofibroma, NOS |
| 9540/1: Neurofibromatosis, NOS |
| 9540/3: Malignant peripheral nerve sheath tumor |
| 9541/0: Melanotic neurofibroma |
| 9550/0: Plexiform neurofibroma |
| 9550/3: Plexiform neurofibrosarcma |
| 9560/0: Neurilemoma, NOS |
| 9560/1: Neurinomatosis |
| 9560/3: Neurilemmoma, malignant |
| 9561/3: MPNST with rhabdomyoblastic differentiation |
| 9562/0: Neurothekeoma |
| 9562/3: Neurothekeoma, malignant |
| 9570/0: Neuroma, NOS |
| 9570/3 |
| 9571/0: Perineurioma, NOS |
| 9571/1: Perineurioma, borderline malignancy |
| 9571/3: Perineurioma, malignant |
| 9580/0: Granular cell tumor, NOS |
| 9580/1 |
| 9580/3: Granular cell tumor, malignant |
| 9581/3: Alveolar soft part sarcoma |
| 9582/0: Granular cell tumor of the sellar region |
| 9590/0 |
| 9590/3: Malignant lymphoma, NOS |
| 9591/3: Malignant lymphoma, non-Hodgkin, NOS |
| 9596/3: B-cell lymphoma, between diffuse large B and HL (composite HL and NHL) |
| 9597/3: Primary cutaneous follicle centre lymphoma |
| 9650/3: Classical Hodgkin lymphoma |
| 9651/3: Lymphocyte-rich classical Hodgkin lymphoma |
| 9652/3: Mixed cellularity classical Hodgkin lymphoma |
| 9653/3: Lymphocyte-depleted classical Hodgkin lymphoma |
| 9654/3: Hodgkin lymphoma, LD, diffuse fibrosis (OBS 2010+) see 9651/3 |
| 9655/3: Hodgkin lymphoma, lymphocytic depleted, reticular |
| 9659/3: Nodular lymphocyte predominant Hodgkin lymphoma |
| 9661/3: Hodgkin granuloma (OBS 2010+) see 9651/3 |
| 9662/3: Hodgkin sarcoma (OBS 2010+) see 9651/3 |
| 9663/3: Nodular sclerosis classical Hodgkin lymphoma |
| 9664/3: Hodgkin lymphoma, nodular sclerosis, cellular phase (OBS) see 9663/3 |
| 9665/3: Hodgkin lymphoma, nodular sclerosis, grade 1 (OBS 2010+) see 9663/3 |
| 9667/3: Hodgkin lymphoma, nodular sclerosis, grade 2 (OBS 2010+) see 9663/3 |
| 9670/3: Malignant lymphoma, small B lymphocytes, NOS (OBS 2010+) see 9823/3 |
| 9671/3: Lymphoplasmacytic lymphoma (NHL) |
| 9673/3: Mantle cell lymphoma |
| 9675/3: Malig lymphoma, mixed small & large cell, diffuse (OBS 2010+) see 9690/3 |
| 9678/3: Primary effusion lymphoma |
| 9679/3: Primary mediastinal (thymic) large B-cell lymphoma |
| 9680/3: Diffuse large B-cell (NHL) lymphoma (DLBCL) |
| 9684/3: Malig. lymphoma, large B, diffuse, immunoblastic (OBS 2010+) See 9680/3 |
| 9687/3: Burkitt lymphoma |
| 9688/3: T-cell histiocyte-rich large B-cell lymphoma |
| 9689/3: Splenic marginal zone (B-cell) lymphoma |
| 9690/3: Follicular lymphoma, NOS |
| 9691/3: Follicular lymphoma, grade 2 |
| 9695/3: Follicular lymphoma, grade 1 |
| 9698/3: Follicular lymphoma, grade 3 |
| 9699/3: Extranodal marginal zone lymphoma of mucosal-assoc. lymphoid tissue-MALT |
| 9700/3: Mycosis fungoides |
| 9701/3: Sezary syndrome |
| 9702/3: Peripheral (mature) T-cell lymphoma, NOS |
| 9705/3: Angioimmunoblastic T-cell lymphoma |
| 9708/3: Subcutaneous panniculitis-like T-cell lymphoma |
| 9709/3: Primary cutaneous T-cell lymphoma |
| 9712/3: Intravascular large B-cell lymphoma |
| 9714/3: Anaplastic large cell (T-cell and Null cell) lymphoma, ALK-positive |
| 9716/3: Hepatosplenic (gamma-delta) T-cell lymphoma |
| 9717/3: Enteropathy-associated T-cell (intestinal) lymphoma |
| 9718/3: Primary cutaneous CD30-pos. T-cell (lymphoma) lymphoproliferative disor. |
| 9719/3: Extranodal NK--/T-cell lymphoma, (nasal and ) nasal type |
| 9724/3: Systemic EBV pos T-cell lymphoprolif dis of child |
| 9726/3: Primary cutaneous gamma-delta T-cell lymphoma |
| 9727/3: Blastic plasmacytoid dendritic cell neoplasm (prec b-cell leuk/lymph) |
| 9728/3: Precursor B-lymphoblastic lymphoma (OBS 2010+) See 9811/3 |
| 9729/3: Precursor T--cell lymphoblastic lymphoma, NOS (OBS 2010+) See 9837/3 |
| 9731/3: Solitary plasmacytoma of bone/plasmacytoma, NOS |
| 9732/3: Plasma cell (multiple) myeloma |
| 9733/3: Plasma cell leukemia (OBS 2010+) See 9732/3 |
| 9734/3: Extraosseous (extramedullary) plasmacytoma |
| 9735/3: Plasmablastic lymphoma |
| 9737/3: ALK positive large B-cell lymphoma |
| 9738/3: Large B-cell lymph HHV8 multicentric Castleman dis |
| 9740/3: Mast cell sarcoma |
| 9741/3: Malignant mastocytosis |
| 9742/3: Mast cell leukemia |
| 9750/1 |
| 9750/3: Malignant histiocytosis (OBS 2010+) see 9751/3 |
| 9751/0 |
| 9751/1: Langerhans cell histiocytosis, NOS |
| 9751/3: Langerhans cell histiocytosis (malignant) (NOS) |
| 9752/0 |
| 9752/1: Langerhans cell histiocytosis, unifocal (OBS 2010+) see 9751/3 |
| 9752/3 |
| 9753/1 |
| 9753/3: Langerhans cell histiocytosis, multifocal, malig (OBS 2010+) see 9751/3 |
| 9754/1: Langerhans cell histiocytosis, disseminated, borderline |
| 9754/3: Langerhans cell histiocytosis, disseminated (OBS 2010+) see 9751/3 |
| 9755/3: Histiocytic sarcoma |
| 9756/3: Langerhans cell sarcoma |
| 9757/3: Interdigitating dendritic cell sarcoma |
| 9758/3: Follicular dendritic cell sarcoma |
| 9760/3: Immunoproliferative disease, NOS (OBS 2010+) see 9761/3 or 9762/3 |
| 9761/3: Waldenstrom macroglobulinemia |
| 9762/3: Heavy chain disease |
| 9764/3: Immunoproliferative small intestinal disease (OBS 2010+) see code 9762 |
| 9765/3: Monocloncal gammopathy, malignant |
| 9766/1: Angiocentric immunoproliferative lesion |
| 9766/3: Angiocentric immunoproliferative lesion, malignant |
| 9768/3 |
| 9769/3: Immunoglobulin deposition disease (malignant) |
| 9800/3: Leukemia, NOS |
| 9801/3: Acute (undifferentiated) leukemia |
| 9805/3: Acute biphenotypic leukemia (OBS 2010+) see codes 9806-9809 |
| 9806/3: Mixed pheno acute leuk w/t(9;22)(q34;q11.2);BCR-ABL1 |
| 9807/3: Mixed phenotype acute leukemia with t(v;11q23); MLL rearranged |
| 9808/3: Mixed phenotype acute leukemia, B/myeloid, NOS |
| 9809/3: Mixed phenotype acute leukemia, T/myeloid, NOS |
| 9811/3: B lymphoblastic leuk/lymph, NOS |
| 9812/3: B lymphobl leuk/lymph w/t(9;22)(q34;q11.2); BCR-ABL1 |
| 9813/3: B lymphobl leuk/lymph w/t(v;11q23); MLL rearranged |
| 9814/3: B lymphobl leuk/lymph w/t(12;21)(p13;q22);TEL-AML1 |
| 9815/3: B lymphoblastic leuk/lymph w/hyperdiploidy |
| 9816/3: B lymphobl leuk/lymph w/hypodiploidy (hypodip ALL) |
| 9817/3: B lymphobl leuk/lymph w/t(5;14)(q31;q32); IL3-IGH |
| 9818/3: B lymphobl leuk/lymph w/t(1;19)(q23;p13.3); E2A PBX1 |
| 9820/3: Lymphoid leukemia, NOS |
| 9823/3: Chronic lymphocytic leukemia/small lymphocytic lymphoma (B-cell) |
| 9826/3: Burkitt cell leukemia |
| 9827/3: Adult T-cell leukemia/lymphoma (HTLV-1 pos.) |
| 9831/3: T-cell large granular lymphocytic leukemia |
| 9832/3: Prolymphocytic leukemia, NOS |
| 9833/3: B-cell prolymphocytic leukemia |
| 9834/3: T-cell prolymphocytic leukemia |
| 9835/3: Precursor cell lymphoblastic leukemia, NOS (OBS 2010+) see 9811/3 |
| 9836/3: Precursor B-cell lymphoblastic leukemia (OBS 2010+) see code 9811/3 |
| 9837/3: Adult T-cell leukemia/lymphoma |
| 9840/3: Acute erythroid leukemia (M6 type) |
| 9860/3: Myeloid leukemia, NOS |
| 9861/3: Acute myeloid leukemia |
| 9863/3: Chronic myeloid leukemia, NOS |
| 9865/3: Acute myeloid leukemia w/t(6;9)(p23;q34) DEK-NUP214 |
| 9866/3: Acute promyelocytic leukemia (AML with t(15;17)(q22;q12)) PML/RARA |
| 9867/3: Acute myelomonocytic leukemia |
| 9869/3: Acute myeloid leuk. inv(3)(q21;q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1 |
| 9870/3: Acute basophilic leukemia |
| 9871/3: AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22), CBFB-MYH11 |
| 9872/3: Acute myeloid leukemia with minimal differentiation |
| 9873/3: Acute myeloid leukemia without maturation |
| 9874/3: Acute myeloid leukemia with maturation |
| 9875/3: Chronic myelogenous leukemia, BCR/ABL positive |
| 9876/3: Atypical chronic myeloid leukemia, BCR/ABL negative |
| 9891/3: Acute monoblastic and monocytic leukemia |
| 9895/3: AML with myelodysplasia-related changes (multilineage dysplasia) |
| 9896/3: Acute myeloid leukemia, t(8;21)(q22;q22) RUNX1-RUNX1T1 |
| 9897/3: Acute myeloid leukemia with t(9;11)(p22;q23);MLLT3-MLL |
| 9898/3: Myeloid leukemia associated w/Down Syndrome |
| 9910/3: Acute megakaryoblastic leukemia |
| 9911/3: Acute myeloid leuk (megakaryobl) w/t(1;22)(p13;q13) |
| 9920/3: Therapy-related (acute) myeloid neoplasm |
| 9930/3: Myeloid sarcoma |
| 9931/3: Acute panmyelosis with myelofibrosis |
| 9940/3: Hairy cell leukemia |
| 9945/3: Chronic myelomonocytic leukemia, NOS |
| 9946/3: Juvenile myelomonocytic leukemia |
| 9948/3: Aggressive NK-cell leukemia |
| 9950/3: Polycythemia vera |
| 9960/3: Chronic myeloproliferative disease, NOS (OBS 2010+) see 9975/3 |
| 9961/3: Primary myelofibrosis/myelosclerosis with myeloid metaplasia |
| 9962/3: Essential thrombocythemia |
| 9963/3: Chronic neutrophilic leukemia |
| 9964/3: Chronic eosinophilic leukemia (hypereosinophilic syndrome), NOS |
| 9965/3: Myeloid and lymphoid neoplasms w/PDGFRA rearrange |
| 9966/3: Myeloid and lymphoid neoplasms w/PDGFRB rearrange |
| 9967/3: Myeloid and lymphoid neoplasm w/FGFR1 abnormalities |
| 9970/1: Lymphoproliferative disorder, borderline |
| 9970/3: Lymphoproliferative disorder (disease), NOS (malig only prior to 2010) |
| 9971/3: Polymorphic PTLD |
| 9975/3: Myelodysp./myeloproliferative neoplasm unclass (malig only before 2010) |
| 9980/3: Refractory anemia |
| 9982/3: Refractory anemia with sideroblasts |
| 9983/3: Refractory anemia with excess blasts |
| 9984/3: Refractory anemia w. excess blasts in transformation |
| 9985/3: Refractory cytopenia with multilineage dysplasia |
| 9986/3: Myelodysplastic syndrome associated with isolated del(5q) |
| 9987/3: Therapy related myelodysplastic syndrome, NOS (OBS 2010+) See 9920/3 |
| 9989/3: Myelodysplastic syndrome, unclassifiable or NOS |
| 9991/3: Refractory neutropenia |
| 9992/3: Refractory thrombocytopenia |

*Summary Stage:* single variable based on SEER Summary Stage 77, 2000, Derived (combined based on dx year)

IS, L, R, D, unknown

*Laterality:*

Not a paired site, Right (origin of primary), Left (origin of primary), Only one side—side unspecified, Bilateral-single primary, Paired site—midline tumor, Paired site—but no information

*Grade:*

|  |
| --- |
| Well differentiated; Grade I |
| Moderately differentiated; Grade II |
| Poorly differentiated; Grade III |
| Undifferentiated; anaplastic; Grade IV |
| T-cell |
| B-cell; pre-B; B-precursor |
| Null cell; non T-non B |
| NK cell; natural killer cell |
| Unknown |

*Diagnostic Confirmation:*

Microscopically confirmed

Positive laboratory test/marker study

Direct visualization without microscopic confirmation

Radiography without microscopic confirm

Clinical diagnosis only

Unknown

*Report Source:* only 2 codes—other; DCO or autopsy only

*MP based on IARC Rules:* check Y/N

*MP based on SEER Rules:* check Y/N

*County-Level Urban/Rural Status:* Based on Beale codes

Metro, Non-Metro, unknown

*County-level poverty****:***Based on ACS % living in poverty rolling 5 year-average (linked to date of diagnosis)

<5%, 5-9.9%, 10-19.99%, 20%+, unknown

*SES Composite (SEER):* YOST based on ACS data, county-level not tract because we do not currently have denominator (US only). Components include: Occupation, Unemployment, Poverty, Income, Education, Housing (price, ownership, crowding).